Clincosm LogoSign in Get a demo

A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation

Sponsor
C. R. Bard (Industry)
Overall Status
Terminated
CT.gov ID
NCT01305486
Collaborator
(none)
4
Enrollment
1
Location
9
Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This will be an observational study designed to collect early, short- and long-term clinical outcomes of the XenMatrix™ Surgical Graft for complex ventral hernia repair. Subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    4 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation
    Study Start Date :
    Sep 1, 2010
    Actual Primary Completion Date :
    Jun 1, 2011
    Actual Study Completion Date :
    Jun 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    XenMatrix

    Outcome Measures

    Primary Outcome Measures

    1. To estimate the hernia recurrence rate of complex ventral hernias post repair with the XenMatrix™ Surgical Graft utilizing the component separation technique with several different tissue plane placements of the graft for up to 24 months post surgery. [2 Years]

      Any hernia which is identified or confirmed by the investigator in approximately the same position as the hernia repair during any follow up visit after a XenMatrix™ surgical graft has been placed will be considered a recurrent hernia.

    Secondary Outcome Measures

    1. To assess perioperative, short-term and long-term complications in subjects with complex hernias repaired with XenMatrix™ Surgical Graft and component separation. [2 Years]

      Procedural and device related AEs collected from surgery until 24 months post surgery.

    2. To assess the procedural time for XenMatrix™ Surgical Graft placement with component separation. [Day 0]

      Procedure time will be defined as beginning when the investigator makes the initial skin incision and ending when the skin closure is completed (skin to skin).

    3. To assess changes in subject quality of life (QOL) post repair with a XenMatrix™ Surgical Graft with component separation. [2 years]

      Changes in QOL will be assessed from baseline to 24 months utilizing the Short Form-36 (SF-36) version 2.

    4. To assess clinical outcomes based on the tissue plane placement of the XenMatrix™ Surgical Graft. [2 years]

      Subjects who have their grafts placed in different tissue planes will have their recurrence rate, complication type and frequency examined to determine if there are any gross differences.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Be able to undergo study procedures.

    • Have signed an Informed Consent form (ICF).

    • Be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator.

    • Requires a component separation repair with the use of a biological graft.

    Exclusion Criteria:

    • Subject is participating in another device or drug study.

    • Subject has a life expectancy less than 4 years at the time of enrollment.

    • Any condition in the opinion of the investigator that would preclude the use of the XenMatrix™ Surgical Graft, or preclude the subject from completing the follow-up requirements.

    • Any subject with a defect the surgeon feels he/she cannot fully close.

    • Subjects with a BMI > 50.

    • Subjects with connective tissue disorders.

    • Subjects with a history of cirrhosis.

    • Subjects with renal failure requiring dialysis.

    • Subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study.

    • Transplant recipients.

    • Subjects taking corticosteroids for >6 months (pre or post surgery).

    • Any bowel leak or infection that would preclude the use of the XenMatrix™ Surgical Graft in the opinion of the investigator.

    • The subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Our Lady of the Lake Regional Medical Center Baton Rouge Louisiana United States 70808

    Sponsors and Collaborators

    • C. R. Bard

    Investigators

    • Principal Investigator: Karl LeBlanc, MD, Our Lady of the Lake Regional Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    C. R. Bard
    ClinicalTrials.gov Identifier:
    NCT01305486
    Other Study ID Numbers:
    • DVL-HE008
    First Posted:
    Feb 28, 2011
    Last Update Posted:
    Jan 15, 2013
    Last Verified:
    Jan 1, 2013
    Additional relevant MeSH terms:
    Hernia
    Hernia, Ventral

    Study Results

    No Results Posted as of Jan 15, 2013